4 results match your criteria: "Peking University School of Oncology and Beijing Cancer Hospital and Institute[Affiliation]"
Zhongguo Fei Ai Za Zhi
February 2008
Peking University School of Oncology and Beijing Cancer Hospital and Institute, Haidian, Beijing, 100036 China.
Can J Microbiol
February 2007
Department of Biochemistry and Molecular Biology, Peking University School of Oncology and Beijing Cancer Hospital and Institute, 52 Fu-Cheng Road, Haidian District, Beijing, 100036 People's Republic of China.
Evidence of Mycoplasma hyorhinis infection in human gastric cancer tissues has been found in previous work. In this study, we demonstrate that the expression of p37, a membrane lipoprotein of M. hyorhinis, in mammalian cells induces antisenescence, enhances clonogenicity in soft agar, and co-operates with human epidermal growth factor receptor-related 2 to inhibit cell adhesion.
View Article and Find Full Text PDFCancer Sci
January 2007
Peking University School of Oncology and Beijing Cancer Hospital and Institute, Haidian, Beijing, China.
Although gastric cancer is the second leading cause of cancer death worldwide, specific and sensitive biomarkers that can be used for its diagnosis are still unavailable. Attempting to improve on current approaches to the serological diagnosis of gastric cancer, we subjected serum samples from 245 individuals (including 127 gastric cancer patients, 100 age- and sex-matched healthy individuals, nine benign gastric lesion patients and nine colorectal cancer patients) for analysis by surface-enhanced laser desorption/ionization (SELDI) mass spectrometry. Peaks were detected with Ciphergen SELDI software version 3.
View Article and Find Full Text PDFWorld J Gastroenterol
June 2006
Department of Cancer Epidemiology, Peking University School of Oncology and Beijing Cancer Hospital and Institute, Beijing, China.
Aim: To compare the one-day quadruple therapy with a standard 7-d triple therapy for H pylori eradication in a rural population of China.
Methods: A total of 396 patients with (13)C-urea breath test positive for H pylori were assigned into two groups: 239 patients received one-day quadruple therapy (amoxicillin 2000 mg qid; metronidazole 500 mg qid; bismuth citrate 900 mg qid and lansoprazole 60 mg once daily) and 157 patients received 7-d standard triple therapy (amoxicillin 1000 mg bid; clarithromycin 500 mg bid and lansoprazole 30 mg bid). All the patients underwent a (13)C-UBT to assess the eradication of H pylori infection six weeks after treatment.